Accumulated clinical trials have revealed that BHGZD achieves satisfactory therapeutic response in the treatment of active RA, alleviating symptoms and signs of the disease such as pain, morning stiffness, joint tenderness, swelling, and deformity, as well as levels of rheumatoid factor (RF), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) especially in RA patients with wind–damp–heat stimulation with a clinical efficiency as high as 90% (Yuan et al., 2019; Wu, 2021). The gene discussed is CRP; the disease is rheumatoid arthritis.